Strategic Focus Target oncology and autoimmune disease portfolios with CatenaBio’s CysTyr Conjugation platform and MPC conjugates to address tumor resistance and enable targeted combination therapies, aligning with pharmaceutical partners seeking novel modalities.

Clinical Momentum Leverage recent SBRSAB and abstracts showcasing modular MPC libraries to engage translational and clinical development teams at biopharma companies pursuing first-in-class therapies and accelerated timelines.

Leadership & Talent Engage senior oncology strategy and early commercialization leadership to partner on co-development models, leveraging their experience from large pharma to accelerate go-to-market strategies.

Funding & Growth Position CatenaBio as an agile, fundable biotech with a mid-range revenue base and recent $8.1M in funding to attract venture capital interest and strategic collaborations for early-stage programs.

Platform Synergies Highlight compatibility with high-value biopharma tech stacks and cloud-enabled workflows to streamline collaboration, data sharing, and GMP-oriented development, creating partner-ready integration opportunities.